Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection
The purpose of this study is to learn if ipilimumab can be given safely at two different doses given to patients with urothelial cancer who are going to have surgery as part of their treatment. The immunological effectiveness of ipilimumab will also be studied.
Urothelial Carcinoma
DRUG: Ipilimumab
Safety of two dose levels of ipilimumab, given prior to surgery, in this patient population., assessed throughout the study
To evaluate anti-cancer immunological activity in blood and tissue samples compared to pre-treatment or control samples., assessed throughout the study
The purpose of this study is to learn if ipilimumab can be given safely at two different doses given to patients with urothelial cancer who are going to have surgery as part of their treatment. The immunological effectiveness of ipilimumab will also be studied.